ARTICLE | Clinical News
Eltrombopag regulatory update
March 15, 2010 7:00 AM UTC
The European Commission approved an MAA from GlaxoSmithKline for Revolade (Promacta - U.S.) eltrombopag to treat thrombocytopenia in adults with chronic idiopathic thrombocytopenic purpura (ITP). Revo...